Keyphrases
Peripheral T-cell Lymphoma
100%
T-cell Lymphoma
68%
Relapsed or Refractory
54%
Brentuximab Vedotin
48%
Lymphoma
47%
Diffuse Large B-cell Lymphoma (DLBCL)
38%
Cutaneous T-cell Lymphoma
35%
Rituximab
33%
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Anaplastic Large Cell Lymphoma
25%
Lenalidomide
25%
Mycosis Fungoides
23%
Initial Treatment
21%
Phase II Study
20%
NCCN Guidelines
20%
Transplant Eligibility
20%
Non-Hodgkin Lymphoma
19%
Progression-free Survival
19%
Hepatosplenic T-cell Lymphoma
17%
Positron Emission Tomography-computed Tomography (PET-CT)
17%
T Cells
16%
Nivolumab
15%
Adult T-cell Leukemia
14%
Histone Deacetylase Inhibitor (HDACi)
14%
R-CHOP
14%
Whole Exome Sequencing
14%
Overall Survival
14%
Angioimmunoblastic T-cell Lymphoma
13%
Mantle Cell Lymphoma
13%
T-follicular Helper Phenotype
13%
Risk Stratification
13%
Cytarabine
13%
Follicular Lymphoma
12%
Previously Untreated
12%
Breast
12%
Primary Mediastinal Large B-cell Lymphoma
12%
Classical Hodgkin Lymphoma
12%
Bendamustine-rituximab
12%
Whole Genome Sequencing
12%
Improved Outcomes
12%
Quality of Life
12%
Lymphoma Patients
11%
Confidence Interval
11%
Natural Killer Cells
10%
Rare Subtype
10%
Objective Response Rate
10%
Breast Implants
10%
Doxorubicin
10%
Cyclophosphamide
10%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
98%
T-Cell Lymphoma
63%
Anaplastic Large Cell Lymphoma
45%
Non-Hodgkin Lymphoma
36%
Brentuximab Vedotin
35%
Disease
33%
Transplantation
33%
Breast Implant
31%
Neoplasm
30%
Cutaneous T Cell Lymphoma
29%
Diffuse Large B-Cell Lymphoma
25%
Lenalidomide
24%
Overall Survival
23%
T Cell
23%
Quality of Life
22%
Rituximab
20%
Progression Free Survival
20%
Malignant Neoplasm
20%
Large-Cell Lymphoma
18%
Mycosis fungoides
18%
CHOP
17%
Positron Emission Tomography-Computed Tomography
16%
Nivolumab
15%
Adult T-Cell Leukemia/Lymphoma
15%
Mantle Cell Lymphoma
13%
Angioimmunoblastic T-Cell Lymphoma
13%
Cytarabine
13%
Bendamustine
12%
Classical Hodgkin Lymphoma
12%
Natural Killer Cell
12%
NK T Cell Lymphoma
12%
Biological Marker
12%
Chemotherapy
11%
Hepatosplenic T-Cell Lymphoma
11%
Cutaneous Lymphoma
11%
Adverse Event
10%
B Cell
10%
Exome Sequencing
9%
Lupus Erythematosus Panniculitis
9%
Stem Cell Transplant
9%
Targeted Therapy
9%
Oncology
8%
Anaplastic Lymphoma Kinase
8%
Romidepsin
8%
Clinical Decision Making
8%
Histone Deacetylase Inhibitor
8%
B-Cell Lymphoma
8%
Minimal Residual Disease
7%
Risk Stratification
7%
Receptor
7%